RESUMO
Numerous studies have linked severe stress to the development of major depressive disorder (MDD) and suicidal behaviors. Furthermore, recent preclinical studies from our laboratory and others have demonstrated that in rodents, chronic stress and the stress hormone cortisol cause oxidative damage to mitochondrial function and membrane lipids in the brain. Mitochondria play a key role in synaptic neurotransmitter signaling by providing adenosine triphosphate (ATP), mediating lipid and protein synthesis, buffering intracellular calcium, and regulating apoptotic and resilience pathways. Membrane lipids are similarly essential to central nervous system (CNS) function because cholesterol, polyunsaturated fatty acids, and sphingolipids form a lipid raft region, a special lipid region on the membrane that mediates neurotransmitter signaling through G-protein-coupled receptors and ion channels. Low serum cholesterol levels, low antioxidant capacity, and abnormal early morning cortisol levels are biomarkers consistently associated with both depression and suicidal behaviors. In this review, we summarize the manner in which nutrients can protect against oxidative damage to mitochondria and lipids in the neuronal circuits associated with cognitive and affective behaviors. These nutrients include ω3 fatty acids, antioxidants (vitamin C and zinc), members of the vitamin B family (Vitamin B12 and folic acid), and magnesium. Accumulating data have shown that these nutrients can enhance neurocognitive function, and may have therapeutic benefits for depression and suicidal behaviors. A growing body of studies suggests the intriguing possibility that regular consumption of these nutrients may help prevent the onset of mood disorders and suicidal behaviors in vulnerable individuals, or significantly augment the therapeutic effect of available antidepressants. These findings have important implications for the health of both military and civilian populations.
Assuntos
Depressão/dietoterapia , Mitocôndrias/fisiologia , Neurotransmissores/metabolismo , Transtornos de Estresse Pós-Traumáticos/dietoterapia , Prevenção do Suicídio , Antioxidantes/administração & dosagem , Colesterol/sangue , Ácidos Graxos Ômega-3/administração & dosagem , Humanos , Hidrocortisona/sangue , Magnésio/administração & dosagem , Militares , Estresse Oxidativo/efeitos dos fármacos , Transdução de Sinais , Privação do Sono/complicações , Estresse Psicológico/complicações , Complexo Vitamínico B/administração & dosagemRESUMO
Bipolar disorder (BPD) is a complex clinical phenomenon. This episodic illness comprises at least four features/components: depression, mania, vulnerability to mood swings in euthymic BPD patients, and spontaneous cyclicity in at least some BPD patients. Currently, there is no rodent genetic model capable of encompassing the whole phenotype of BPD exists; however, recent genetic-behavioral studies have delineated partial models for some components of BPD, namely, depression, mania, and vulnerability or resilience to mood swings. p11 knockout (KO), vesicular monoamine transporter 2 (VMAT2) heterozygous KO, and neural cell adhesion molecule (NCAM) KO mice display anhedonia-like symptoms, and treatment with antidepressants rescues this anhedonia-related phenotype. Mutant CLOCK, glutamate receptor 6 (GluR6) KO, and extracellular signal-regulated kinase 1 (ERK1) KO mice exhibit mania-like behavioral clusters referred to as excessive behavioral excitement; at least some of the exhibited behaviors can be rescued through treatment with mood stabilizers or atypical antipsychotics. Neuronal glucocorticoid receptor (GR) overexpressing, B-cell lymphoma 2 (Bcl-2) heterozygous KO, and Bcl-2-associated athanogene (BAG1) heterozygous KO mice show vulnerability to mood swings. In contrast, neuronal BAG1 overexpressing mice display resilience to mood swings. These mutant mouse strains and the behavioral approaches used to characterize these strains offer an emerging set of research tools for the comprehensive understanding of various components of BPD, and the interrelation of these components at the molecular, cellular, and neuronal circuitry levels. These partial genetic models can also be used as complementary tools to augment other existing behavioral tests and paradigms in drug development for BPD.
Assuntos
Transtorno Bipolar , Transtorno Depressivo , Modelos Genéticos , Animais , Transtorno Bipolar/genética , Humanos , Camundongos , Transtornos do Humor , RoedoresRESUMO
Accumulating evidence suggests that psychotropic agents such as mood stabilizers, antidepressants, and antipsychotics realize their neurotrophic/neuroprotective effects by activating the mitogen activated protein kinase/extracellular signal-related kinase, PI3-kinase, and wingless/glycogen synthase kinase (GSK) 3 signaling pathways. These agents also upregulate the expression of trophic/protective molecules such as brain-derived neurotrophic factor, nerve growth factor, B-cell lymphoma 2, serine-threonine kinase, and Bcl-2 associated athanogene 1, and inactivate proapoptotic molecules such as GSK-3. They also promote neurogenesis and are protective in models of neurodegenerative diseases and ischemia. Most if not all, of this evidence was collected from animal studies that used clinically relevant treatment regimens. Furthermore, human imaging studies have found that these agents increase the volume and density of brain tissue, as well as levels of N-acetyl aspartate and glutamate in selected brain regions. Taken together, these data suggest that the neurotrophic/neuroprotective effects of these agents have broad therapeutic potential in the treatment; not only of mood disorders and schizophrenia, but also neurodegenerative diseases and ischemia.